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IMPORTANCE Use of thiopurines may be limited bymyelosuppression. TPMT
pharmacogenetic testing identifies only 25% of at-risk patients of European ancestry.
Among patients of East Asian ancestry, NUDT15 variants are associated with
thiopurine-inducedmyelosuppression (TIM).
OBJECTIVE To identify genetic variants associated with TIM among patients of European
ancestry with inflammatory bowel disease (IBD).
DESIGN, SETTING, AND PARTICIPANTS Case-control study of 491 patients affected by TIM and
679 thiopurine-tolerant unaffected patients who were recruited from 89 international sites
betweenMarch 2012 and November 2015. Genome-wide association studies (GWAS) and
exome-wide association studies (EWAS) were conducted in patients of European ancestry.
The replication cohort comprised 73 patients affected by TIM and 840 thiopurine-tolerant
unaffected patients.
EXPOSURES Genetic variants associated with TIM.
MAIN OUTCOMES ANDMEASURES Thiopurine-inducedmyelosuppression, defined as a decline
in absolute white blood cell count to 2.5 × 109/L or less or a decline in absolute neutrophil cell
count to 1.0 × 109/L or less leading to a dose reduction or drug withdrawal.
RESULTS Among 1077 patients (398 affected and 679 unaffected; median age at IBD
diagnosis, 31.0 years [interquartile range, 21.2 to 44.1 years]; 540 [50%] women; 602 [56%]
diagnosed as having Crohn disease), 919 (311 affected and 608 unaffected) were included in
the GWAS analysis and 961 (328 affected and 633 unaffected) in the EWAS analysis. The
GWAS analysis confirmed association of TPMT (chromosome 6, rs11969064) with TIM
(30.5% [95/311] affected vs 16.4% [100/608] unaffected patients; odds ratio [OR], 2.3 [95%
CI, 1.7 to 3.1], P = 5.2 × 10−9). The EWAS analysis demonstrated an association with an
in-frame deletion in NUDT15 (chromosome 13, rs746071566) and TIM (5.8% [19/328]
affected vs 0.2% [1/633] unaffected patients; OR, 38.2 [95% CI, 5.1 to 286.1], P = 1.3 × 10−8),
which was replicated in a different cohort (2.7% [2/73] affected vs 0.2% [2/840] unaffected
patients; OR, 11.8 [95% CI, 1.6 to 85.0], P = .03). Carriage of any of 3 coding NUDT15 variants
was associated with an increased risk (OR, 27.3 [95% CI, 9.3 to 116.7], P = 1.1 × 10−7) of TIM,
independent of TPMT genotype and thiopurine dose.
CONCLUSIONS AND RELEVANCE Among patients of European ancestry with IBD, variants in
NUDT15were associated with increased risk of TIM. These findings suggest that NUDT15
genotypingmay be considered prior to initiation of thiopurine therapy; however, further
study including additional validation in independent cohorts is required.
JAMA. 2019;321(8):773-785. doi:10.1001/jama.2019.0709
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T hiopurines (mercaptopurine and its prodrug azathio-prine) are commonly used in the management of in-flammatory bowel disease (IBD). However, approxi-
mately 15% of patients develop adverse drug reactions that
necessitate drug withdrawal.1,2 Thiopurine-induced myelo-
suppression (TIM) has a cumulative incidence of 7%andusu-
ally occurs within a fewweeks of starting the drug.1 Most pa-
tients are asymptomatic, but serious opportunistic infections
may occur and there is an estimated mortality of 1%.1
The enzyme thiopurine S-methyltransferase (TPMT) con-
verts thiopurines tomethylatedmetabolites, reducing thepro-
duction of active 6-thioguanine nucleotides.3 Genetic varia-
tion in the TPMT gene (RefSeqGene NG_012137.2) can result
in decreasedTPMTenzyme activity andhigher production of
6-thioguaninenucleotides,predisposingpatients tobonemar-
row suppression.1,3,4 Pretreatment testing of TPMT is recom-
mended by the US Food and Drug Administration to identify
patients at risk of TIM.5 Among patients with reduced TPMT
activity, the drugmay be avoided or the dose reduced.6 How-
ever, TPMT variants are only found in 25% of patients of
European ancestry affected by TIM, suggesting the presence
of other genetic and environmental determinants.6,7 Studies
inpatients ofEastAsianancestry8,9 andotherpopulations10-14
have identified variants in nudix hydrolase 15 (NUDT15;
RefSeqGene NG_047021.1) as risk factors for TIM. Although a
novelNUDT15variant (rs746071566,p.Gly17_Val18del)wasde-
scribed by Moriyama et al10 in a single pediatric patient of
European ancestry affected by TIM, the association of the
NUDT15 genetic variationwith TIM in this population has not
been fully evaluated.
The primary objective of this studywas to investigate the
association between genetic variants and TIM in patients of
European ancestrywith IBD. Itwashypothesized that the fre-
quency of these variants would be increased among patients
affected by TIM and enriched in those with early-onset TIM
(≤8 weeks from start of maximum dose).1
Methods
Study Design and Setting
TheprotocolwasapprovedbytheNationalResearchEthicsCom-
mittee (11/SW/0222, Exeter pharmacogenetic PRED4 program
and STB1, Exeter IBD Genetics cohort, England). All partici-
pantsprovided informedwrittenconsent.A retrospectivecase-
control studyof theassociationofgeneticvariantswithTIMwas
designed as part of the Exeter pharmacogenetic PRED4 pro-
gram,which aims to investigate the genetic basis of serious ad-
verse reactions among patients prescribed commonly used
drugs in gastroenterology (http://www.ibdresearch.co.uk).15,16
Platformsforbothgenome-wideassociationstudies (GWAS)and
exome-wideassociationstudies(EWAS)wereusedtoinvestigate
common and rare genetic variation, respectively.
Study Populations and Case Definition
Thiopurine-induced myelosuppression cases (affected pa-
tients) were recruited from 82 sites within the United King-
dom and from 7 sites outside the United Kingdom between
March2012andNovember2015andnot followedupafter their
single study visit. Individuals affected by TIM were identi-
fied through clinical encounters, systematic searches of elec-
tronic records, recall via the Medicines and Healthcare Prod-
ucts Regulatory Agency Yellow Card Scheme, and by direct
advertising to patients.
Inclusion criteria included all of the following: diagnosis
of IBD, history of thiopurine exposure during the 7 days prior
to the onset of TIM, decline in absolutewhite blood cell count
to2.5 × 109/Lor lessordecline inabsoluteneutrophil cell count
to 1.0 × 109/L or less, and determination by the treating phy-
sician that use of a thiopurinewas the likely cause of TIM and
the dose was reduced or the drug was withdrawn.
Investigators at each site completed a custom-designed
case report form (eAppendix 1 in the Supplement) that cap-
tured the following data: patient demographics (age, weight,
height, ethnicity, and smoking history), adverse drug reac-
tion data (type of thiopurine, dose, drug start and stop date,
full blood cell count parameters before, during, and after ex-
posure to thedrug, and full blood cell count normal range ref-
erence values), and IBD phenotype. Each patient was diag-
nosed as having IBD by his or her gastroenterologist using
endoscopicdata, histological data, radiological data, or a com-
bination of these, and phenotyped according to theMontreal
classification of IBD.17 TheMontreal system classified the ex-
tent of ulcerative colitis as limited to the rectum (E1), distal to
the splenic flexure (E2), or proximal to the splenic flexure (E3).
For Crohn disease, patients were categorized by age at dis-
ease onset (A1: <17 years, A2: 17-40 years, or A3: >40 years),
locationofdisease (L1: ileal, L2: colonic,orL3: ileocolonic), and
disease behavior (B1: nonstricturing and nonpenetrating, B2:
stricturing, or B3: penetrating).
Consistent with our prior pharmacogenetics studies,15,16
the case report forms of all recruited patients affected by TIM
were reviewed independently by at least 4 gastroenterolo-
gists andassignedanadjudication category (eAppendices 2-4,
eFigure 1, and eMethods in the Supplement).18 Only patients
assigned as definitely or probably affected by TIM were in-
cluded in the discovery and replication analyses.
Thiopurine-exposed controls without TIM (unaffected
patients)were identified from the Exeter IBDGenetics cohort
recruited at the Royal Devon and Exeter Hospital (additional
Key Points
Question What genetic variants are associated with
thiopurine-inducedmyelosuppression among patients of
European ancestry with inflammatory bowel disease?
Findings In this case-control study that used whole-exome
sequence data from 961 thiopurine-exposed patients of European
ancestry with inflammatory bowel disease, 3 coding NUDT15
variants, including a 6–base pair in-frame deletion (odds ratio,
38.2), were identified that were associated with
thiopurine-inducedmyelosuppression.
Meaning Among patients of European ancestry with
inflammatory bowel disease, variants in NUDT15were associated
with increased risk of thiopurine-inducedmyelosuppression.
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details appear in the eMethods in the Supplement). In the fi-
nal analyses, only patients with an absolute white blood cell
count of 3.0 × 109/L or greater and an absolute neutrophil cell
count of 1.5 × 109/L or greater for the duration of their treat-
ment with a thiopurine were included.
The replication cohortmet the identical inclusion criteria
and included nonoverlapping patients from the same central
studysite (RoyalDevonandExeterHospital) andpatients from
4newsites (Saint-AntoineHospital inFrance,UniversityMedi-
cal Center Groningen in the Netherlands, Cedars-Sinai Medi-
calCenter in theUnitedStates, andMassachusettsGeneralHos-
pital in the United States). Patients at these new sites were
identified fromsearchesofpreexistinggenetics cohorts inApril
2017. These sites had started recruitment in 2005 (Massachu-
setts GeneralHospital andCedars-SinaiMedical Center), 2011
(University Medical Center Groningen), and 2013 (Saint-
Antoine Hospital).
Genetic Analysis
Details of genetic data generation and quality control prior to
the GWAS and EWAS analyses appear in the eMethods in the
Supplement.FortheGWASanalysis,245185variantsweregeno-
typed using the Illumina Infinium G4L GWAS array. Patients
were excluded if they had variants with a call rate of less than
98%,hadvariantswithaminorallele frequencyof less than1%,
orhadvariantswithaHardyWeinbergequilibriumofP < 1 × 10−6
amongunaffected patients. The principal component analysis
wascarriedoutusingGenome-wideComplexTraitAnalysisver-
sion1.2419 toassessdatafromthe1000GenomesProject.20Only
data from patients clustering with non-Finnish European pa-
tientswere included.Thisprocessminimizedthepotential con-
foundingeffectsofpopulationstratification,whichmighthave
resulted in an association with variants and TIM even though
the association was with a specific ethnicity, which was by
chance overrepresentated or underrepresented among af-
fected patients comparedwith unaffected patients.
We excluded patients of Finnish ancestry because their
unique genetic background, which has occurred as a conse-
quenceofgeographical andcultural isolation,has led to theen-
richment of some disease-causing gene variants and losses
of others. Other quality control measures included a sex-
mismatch check (amethod that usedX chromosomehomozy-
gosity rates todeterminesexand identifypatients forwhomthe
sex recorded in thecase report formorphenotypedatabasedid
not match the predicted sex based on genetic data) and relat-
edness checking (inwhich sample and pedigree integritywere
bothsimultaneouslyexaminedbyreconcilinggenomicdatawith
self-reported relationships between patients).
After prephasing with the Eagle2 algorithm,21 imputation
with thepositional Burrows-Wheeler transform22methodwas
performedusing phase 3 of the 1000Genomes Project20 refer-
encepanel and theWellcomeTrust Sanger ImputationService.
Only single-nucleotide polymorphismswith a postimputation
information score of less than0.85 or aminor allele frequency
of less than0.01were included.Afterall thequalitycontrolmea-
sureswere implemented, 6272335 variants remained.
FortheEWASanalysis,exonicregionsweresequencedusing
the IlluminaHiSeq platform (150 base-paired reads) and reads
mapped to theGenomeReferenceConsortiumhumanbuild37
using theBurrows-WheelerAlignmentMEMalgorithm.23Each
samplewassequenced toanaveragedepthof34 timeswithap-
proximately 99% of the targeted regions covered by 1 time or
greater, approximately92%coveredby 10 timesorgreater, and
approximately70%coveredby25timesorgreater.Variantswith
a Hardy Weinberg equilibrium of P < 1 × 10−6 were excluded
along with any variants that had a genotyping success rate of
less than0.98, a readdepthof less than 10 times, or a genotype
skewofP < 5 × 10−9 (binomial test).Forqualitycontrol after the
EWAS analysis, a quantile-quantile plotwas used (eFigure 2 in
the Supplement).
Statistical Analysis
Phenotype Comparisons
Continuous data were summarized using medians and inter-
quartile ranges (IQRs) and were compared using the Mann-
Whitney test. The estimate of themediandifference between
patients affected byTIMandunaffected patients and95%CIs
also were calculated using R version 3.5.1 (R Foundation for
Statistical Computing). Categorical data were summarized as
the number and percentage and compared using the Fisher
exact test.
Primary Analyses
Associations for both the GWAS and EWAS analyses were de-
termined using the Fisher exact test and PLINK version 1.9
(Cog Genomics). Manhattan plots were generated using
R software to display negative log10 P values at each single-
nucleotidepolymorphism.Agenome-widesignificancethresh-
old ofP < 5 × 10−8was deemed significant. Gene burden tests
using PLINK sequence 0.10 and sequence kernel association
tests24 were used to evaluate if an association existed be-
tween sets of rare variants across individual candidate genes
andpatients affectedbyTIM.Technical validationof the vari-
antswascarriedoutusingSanger sequencing (eMethods in the
Supplement). For the replication cohort, case adjudication,
genotype data generation, genetic quality control, and other
analyseswereundertakenusing thesameplatformsandmeth-
ods as the discovery cohort. Replicated variantswith a Fisher
exact P < .05 were considered significant.
Exploratory Analyses
After findinganassociationwithavariantandTIM,thefinaldata
set was examined for any other nonmonomorphic variants
withinNUDT15 annotated asmissense or as loss of function in
the Genome Aggregation Database (gnomAD).25 Further mis-
sense variants were evaluated using in silico Protein Variation
Effect Analyzer.26 Because the functional significance of this
modeling is uncertain, only replicated NUDT15 variants and
those previously described in other TIM cohorts8,9 were used
insubsequentgenotype-phenotypeanalyses,multivariable lo-
gistic regression analyses, and clinical usefulness analyses.
Combinations of TPMT variants on the same chromo-
some have been reported as haplotypes; these were recon-
structed using the Eagle2 algorithm21 and matched to the
Clinical Pharmacogenetics Implementation Consortium
definitions.27 Categorical TPMT enzyme activity (ie, absent,
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low, normal, or high) was measured in red blood cells using
radiometric high-performance liquid chromatography as part
of routine clinical practice. The relationship between TPMT
haplotypes and enzyme activity was determined.
Genotype-phenotype interactionswereexploredusing the
Mann-Whitney testandtheFisherexact test.All statistical tests
were 2-sided and P < .05 was considered significant. No ad-
justment of the P value was made for multiple comparisons
of phenotype data; therefore, the results of these analyses
should be considered exploratory. Weight-adjusted dose
(milligrams per kilograms) was calculated using the follow-
ing formulas for mercaptopurine (mercaptopurine dose in
milligrams × 2.08/weight in kilograms) and azathioprine
(azathioprine dose in milligrams/weight in kilograms).
A multivariable logistic regression analysis was under-
takentoassess the independentassociationsofNUDT15,TPMT,
and weight-adjusted thiopurine dose with risk of TIM. Time
to TIM (stratified by genotype)was analyzed using theMann-
Whitney test.
Thepotential for clinicalusefulness (sensitivity, specificity,
negative and positive predictive values) of genotyping for vari-
antsassociatedwithTIMwasestimatedusingmethodsadapted
fromTonket al28 anddeGraaff et al29 (eMethods in theSupple-
ment).TheestimatesassumedanoverallriskofTIMof7%,1either
avoidance of the drug (reducing risk of TIM to 0) or target dose
reduction inthosepatientscarryingdeleteriousvariants (reduc-
ing riskofTIMto that seen inpatientswith the referencehaplo-
typeorgenotype), thenon-FinnishEuropeanpopulationvariant
carrier frequency from gnomAD,25 and the odds ratio (OR) of
TIMfor thevariant inmultivariable logistic regressionanalysis.
The95%CIsfor thenumberofpatientsneededtogenotypewere
estimatedusing10000bootstrapsfromthecase-controlcohort,
fromrandomlygeneratedestimatesof thepopulationwithcar-
riageofNUDT15andTPMTvariants,andfromTIMratesthatwere
based on sampling frombinomial distributions. For TPMT, de-
tailed information appears in eMethods in the Supplement.
TheprevalenceofNUDT15variants inpatients of other an-
cestry was explored using all affected patients and popula-
tion data from gnomAD.25
Results
Study Overview
Participant flow through the study appears inFigure 1. In this
case-control study,491patientswith IBDandTIM(affectedpa-
tients)were recruited from82UKand7 international sites be-
tween March 2012 and November 2015. One UK center re-
cruited 843 thiopurine-exposed patients with IBD and no
history of TIM (unaffected patients). Following the adjudica-
tion process, 1077 patients (398 affected and 679 unaffected
patients) entered the final analysis.
After assessment using the genetic quality control mea-
sures, 70 affected patients were excluded (68 for ethnicity, 1
for relatedness, and 1 for sexmismatch) and46unaffectedpa-
tients were excluded (31 for ethnicity, 13 for relatedness, and
2 for sexmismatch). In addition, for the GWAS analysis, 17 af-
fectedpatientswere excluded (10due to failureof quality con-
trol genotyping and 7 to failure of genotyping) and 25 unaf-
fected patients were excluded (23 due to failure of quality
control genotyping and 2 to failure of genotyping). Thus, 919
patients (311 affected and 608 unaffected patients) were in-
cluded in theGWASand961patients (328affectedand633un-
affected patients) were included in the EWAS analysis. Repli-
cation was conducted in 73 affected and 840 unaffected
patients recruited from 5 international sites.
Figure 1. FlowDiagram and Study Overview of Case and Control Cohorts
93 Excluded (possibly or unlikely
affected by thiopurine-induced
myelosuppression)
311 Included in primary analysis for
genome-wide association studies
328 Included in primary analysis for
exome-wide association studies
87 Excluded
68 Ethnicitya
10 Genotype quality control failed
7 Initial genotyping failed
1 Relatednessb
1 Sex mismatchc
398 Probably or definitely affected by
thiopurine-induced myelosuppression
164 Excluded (minor decline in white
blood cell count, neutrophil count,
or both)
608 Included in primary analysis for
genome-wide association studies
633 Included in primary analysis for
exome-wide association studies
71 Excluded
31 Ethnicitya
23 Genotype quality control failed
2 Initial genotyping failed
13 Relatednessb
2 Sex mismatchc
679 Not affected by thiopurine-induced
myelosuppression
491 Patients assessed for thiopurine-
induced myelosuppression
Case Cohort
843 Patients assessed for thiopurine-
induced myelosuppression
Control Cohort
a Indicates non-Finnish European ancestry based on principal component analysis.
b Indicates patients too closely related to each other.
c Indicates a discrepancy between genetically determined sex and phenotype
data.
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Phenotype Comparisons
There were no differences in sex when comparing affected
and unaffected patients (female 53.0% [211/398] vs 48.5%
[329/679], respectively, P = .17; Table 1). There were no dif-
ferences when comparing affected and unaffected patients
by type of IBD diagnosis: Crohn disease (57.8% [230/398] vs
54.8% [372/679], respectively), ulcerative colitis (39.7%
[158/398] vs 44.0% [299/679]), and IBD-unclassified (2.5%
[10/398] vs 1.2% [8/679], P = .12).
There were no differences in behavior of IBD when
comparing affected and unaffected patients using the
Montreal classificationof IBD:B1 (nonstricturing andnonpen-
etrating, 57.7% [123/213] vs 58.9% [175/297], respectively), B2
(stricturing, 29.1% [62/213] vs 27.6% [82/297]), and B3 (pen-
etrating, 13.1% [28/213] vs 13.5%[40/297],P = .94). Therewere
no differences in the extent of ulcerative colitis and IBD-
unclassified when comparing affected and unaffected pa-
tients using theMontreal Classification system: E1 (limited to
the rectum, 9.4% [15/160] vs 6.0% [14/234], respectively), E2
(distal to the splenic flexure, 45.6% [73/160] vs 47.9% [112/
234]), andE3 (proximal to the splenic flexure, 45.0% [72/160]
vs 46.2% [108/234], P = .46).
In contrast, affected patients were younger at the time of
IBD diagnosis (median, 30.1 years [IQR, 19.3-43.1 years]) com-
pared with unaffected patients (median, 31.6 years [IQR,
22.2-44.7 years], P = .02) and received a higher weight-
adjusted thiopurine dose (median, 2.07 mg/kg [IQR, 1.69-
2.45 mg/kg] vs 1.84 mg/kg [IQR, 1.48-2.19 mg/kg], respec-
tively, P < .001). In addition, affected patients with Crohn
disease were more likely to have colonic or ileo-colonic dis-
ease than unaffected patients (L1 [ileal]: 24.9% [57/229] vs
44.0% [132/300], respectively; L2 [colonic]: 32.3% [74/229]
vs 26.3% [79/300], and L3 [ileocolonic]: 42.8% [98/229] vs
29.7% [89/300], P < .001).
Among the 398 affected patients, 143 (36%) episodes of
TIM occurred within 8 weeks of therapy with the maximum
dose of thiopurine (eTable 1 in the Supplement). Themedian
timefromcommencementof thiopurine toTIMwas28.3weeks
(IQR,9.0-81.1weeks)andthemediantimefrommaximumdose
of thiopurine to TIM was 14.7 weeks (IQR, 5.9-37.9 weeks).
Phenotype data for the replication cohort appear in eTable 2
in the Supplement.
Primary Analyses
GWAS Analysis
Data from 311 affected and 608 unaffected patients (eTable 3
in the Supplement) were included in the GWAS discovery co-
hort. TheassociationofTIMwithTPMT (rs11969064)wascon-
firmed in 30.5% (95/311) of affected patients compared with
16.4% (100/608) of unaffected patients (OR, 2.3 [95% CI, 1.7
Table 1. Characteristics of PatientsWith Inflammatory Bowel Disease (IBD) by Thiopurine-Induced
Myelosuppression (TIM) Status
Characteristic
Individuals Affected by TIM
(n = 398)a
Thiopurine-Tolerant
Unaffected Individuals
(n = 679)
Sex, No. (%)
Female 211 (53.0) 329 (48.5)
Male 187 (47.0) 350 (51.5)
Type of IBD diagnosis, No. (%)
Crohn disease 230 (57.8) 372 (54.8)
Ulcerative colitis 158 (39.7) 299 (44.0)
IBD-unclassified 10 (2.5) 8 (1.2)
Age at diagnosis of IBD, median (IQR), yb 30.1 (19.3-43.1) 31.6 (22.2-44.7)
Weight-adjusted thiopurine dose, median (IQR), mg/kgc 2.07 (1.69-2.45) 1.84 (1.48-2.19)
Montreal Classification of IBD, No./total (%)d
Age range at diagnosis
A1: <17 y 52/229 (22.7) 23/300 (7.7)
A2: 17-40 y 122/229 (53.3) 235/300 (78.3)
A3: >40 y 55/229 (24.0) 42/300 (14.0)
Disease location
L1: ileal 57/229 (24.9) 132/300 (44.0)
L2: colonic 74/229 (32.3) 79/300 (26.3)
L3: ileocolonic 98/229 (42.8) 89/300 (29.7)
Behavior of IBD
B1: nonstricturing and nonpenetrating 123/213 (57.7) 175/297 (58.9)
B2: stricturing 62/213 (29.1) 82/297 (27.6)
B3: penetrating 28/213 (13.1) 40/297 (13.5)
Extent of ulcerative colitis and IBD-unclassified
E1: limited to the rectum 15/160 (9.4) 14/234 (6.0)
E2: distal to the splenic flexure 73/160 (45.6) 112/234 (47.9)
E3: proximal to the splenic flexure 72/160 (45.0) 108/234 (46.2)
Abbreviation: IQR, interquartile
range.
a Adjudicated prior to genomic
quality control.
b The estimate of difference was 2.3
(95% CI, 0.4-4.2).
c Represents themaximum
mercaptopurine or azathioprine
equivalent dose prior to TIM
and adjusted for weight:
(mercaptopurine dose in
milligrams × 2.08)/weight in
kilograms) or (azathioprine dose
in milligrams/weight in kilograms).
The estimate of difference was
−0.24 (95% CI, −0.32 to −0.17).
dDetails on theMontreal
classification of IBD system
reported by Silverberg et al.17
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to 3.1], P = 5.2 × 10−9; eFigure 3 in the Supplement). This as-
sociationwas enriched in patients affected early (≤8weeks of
startingmaximumthiopurinedose;OR,4.0[95%CI,2.8 to5.8],
P = 1.8 × 10−15) comparedwiththoseaffected later (OR, 1.6 [95%
CI, 1.1 to 2.2], P = .01; eFigure 4 in the Supplement). No other
genetic associationswithTIMexceeded the a priori threshold
for statistical significance.
EWAS Analysis
Data from 328 affected and 633 unaffected patients were
included in the EWAS discovery cohort (eTable 4 in the
Supplement). TheEWASanalysis,whichwasperformed to in-
vestigate the role of rare coding variants, revealed a TIM as-
sociation with a 6–base pair in-frame deletion at position
48611918of chromosome13 inexon1ofNUDT15 (rs746071566,
p.Gly17_Val18del) for5.8%(19/328)of theaffectedpatientscom-
pared with 0.2% (1/633) of the unaffected patients (OR, 38.2
[95%CI, 5.1 to 286.1],P = 1.3 × 10−8;Figure 2). Comparedwith
unaffected patients, the OR was 74.2 (95% CI, 9.6 to 573.5,
P = 8.2 × 10−10) for patients affectedwith early-onset TIMand
was 20.9 (95% CI, 2.6 to 170.1, P = 4.2 × 10−4) for patients af-
fected with late-onset TIM. The patients affected with early-
onsetTIMwere significantlyenrichedwith thevariant (OR, 3.6
[95% CI, 1.4 to 9.2], P = .005; eTable 5 in the Supplement).
The association of the p.Gly17_Val18del variant and TIM
was confirmed in the replication cohort analysis among
2.7% (2/73) of the affected patients with IBD compared with
0.2% (2/840) of the unaffected patients (OR, 11.8 [95% CI,
1.6 to 85.0], P = .03). A duplication at this multiallelic site
within NUDT15 (rs746071566, p.Gly17_Val18dup [also anno-
tated as p.Val18_Val19insGlyVal]) was noted; however, the
duplication did not meet genome-wide significance (1.5%
[5/328] of affected patients vs 0.3% [2/633] of unaffected
patients; OR, 5.2 [95% CI, 1.0 to 26.6], P = .04; Table 2). The
only variant outside of NUDT15 significantly associated with
TIM in the exome sequencing data was rs1800460 in TPMT
(OR, 3.0 [95% CI, 2.0 to 4.3], P = 2.0 × 10−8). Gene burden
testing did not identify any novel associations beyond
TPMT and NUDT15 (eTable 6 in the Supplement).
Exploratory Analyses
Sequencedata forNUDT15were examined for thepresence of
all coding variants either previously associated with TIM8-10
or identified in gnomAD25 and predicted as deleterious using
the Protein Variation Effect Analyzer26 (Table 2 and eFigure 5
in the Supplement). However, 4 (p.Lys33Glu, p.Val75Gly,
p.Cys28GlyfsTer28,andp.Met1?)of the7NUDT15variantswere
each only found in a single individual. Therefore, only vari-
ants eithermeeting genome-wide association in this analysis
(p.Gly17_Val18del) or previously associatedwith TIM in other
analyses (p.Arg139Cys and p.Gly17_Val18dup) were included
for subsequent exploratory analyses.
Overall, 9.5% (31/328) of the non-Finnish European TIM
discovery cohort carry any of the 3 NUDT15 coding variants
comparedwith 0.5% (3/633) of unaffected patients (OR, 20.9
[95%CI,6.4 to68.6],P = 1.5 × 10−12).Theassociationwiththese
NUDT15variantswas enriched inpatients affectedwith early-
onset vs late-onset TIM (OR, 3.3 [95%CI, 1.6 to 6.9],P < .001).
Of the included patients in the EWAS analysis (discov-
ery cohort), 75% (717/961) had TPMT activity levels available
for analysis. All 10 patients with absent TPMT activity and
73% of patients (80/109) with low TPMT activity carried
variant TPMT haplotypes (eFigure 6 and eTables 7-9 in the
Supplement). Overall, 4.9% (16/328) of affected patients and
0.2% (1/633) of unaffected patients had 2 TIM-associated
TPMT variant haplotypes.
Figure 2. Manhattan Plot for the Discovery Exome-Wide Association Studies Analysis Among 328 Individuals
Affected by Thiopurine-InducedMyelosuppression and 633 Thiopurine-Tolerant Unaffected Individuals
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Genotype-Phenotype Analyses
Among all affected patients in the EWAS analysis, themedian
time to TIMwas 15weeks (IQR, 6-41weeks) and 34% (111/328)
experienced early-onset TIM. Of note, 18% (59/328) pre-
sentedwith anopportunistic infection, 23% (77/328)were ad-
mitted toahospitalwithamedian lengthof stayof6days (IQR,
2-9 days), and 9% (31/328) required granulocyte colony–
stimulating factor rescue therapy.
The median time to TIM was shorter in affected patients
who carried NUDT15 variants compared with affected pa-
tients without risk variants (7.7 weeks [IQR, 5.7-20.0 weeks]
vs 20.0 weeks [IQR, 7.6-48.3 weeks], respectively; P = .009)
and inthosewhocarrieddoubleTPMTvariants (6.1weeks [IQR,
4.2-7.6 weeks] vs 20.0 weeks [IQR, 7.6-48.3 weeks], respec-
tively; P = .002).
Themedian time toTIMwas shortest inpatientswithboth
TPMT andNUDT15 variants compared with affected patients
without risk variants (2.5 weeks [IQR, 1.5-4.1 weeks] vs 20.0
weeks [IQR, 7.6-48.3 weeks], respectively, P < .001; Figure 3
andeFigure6 in theSupplement).Nodifference in time toTIMTa
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Figure 3. Box Plot for Time to Thiopurine-InducedMyelosuppression
Among Affected Individuals Defined byNUDT15 and TPMTGenotype
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Data points are each represented by a dot. The lower and upper boundaries of
the box correspond to the first and third quartiles. The line within the box
represents themedian. The upper whisker extends from the upper boundary of
the box to the largest value no further than 1.5 × the interquartile range (IQR).
The lower whisker extends from the lower boundary of the box to the lowest
value, at most no further than 1.5 × the IQR. The time to thiopurine-induced
myelosuppression (TIM) was calculated using the following formula: (time to
TIM in weeks) = date meeting entry criteria for TIMminus start date of highest
dose prior to TIM). Themedian values and IQRs are provided to facilitate
interpretation of time to TIM. One TIM case carried 2NUDT15 variants
(rs746071566 [p.Gly17_Val18dup] and rs116855232 [p.Arg139Cys]); however, it
was unknown if this represented a compound heterozygote or a heterozygote
(*2 NUDT15 haplotype). For the purpose of the analysis, this patient was
grouped with NUDT15 heterozygotes and annotated asNUDT15var/*. One TIM
case was TPMTvar/var and NUDT15var/ref; for the purpose of the analysis, this
patient was grouped with 5 others who carried singleNUDT15 and TPMT
variants (TPMTvar/ref and NUDT15var/ref). Compared with the leftmost group, the
Mann-Whitney P values for the differences in time to onset of TIMwere .14,
.009, .002, and <.001, respectively. Ref indicates reference genotype or
haplotype; var, variant.
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was seen in patients carrying 1 variant TPMT haplotype com-
paredwith affectedpatientswithout risk variants (13.9weeks
[IQR, 5.9-40.4weeks] vs 20.0weeks [IQR, 7.6-48.3weeks], re-
spectively, P = .14).
Patients carrying either NUDT15 or TPMT and those with
variants for both genes developed lower neutrophil counts
than affected patients without these variants (median,
0.8 × 109/L [IQR, 0.4-1.1 × 109/L] vs median, 1.0 × 109/L [IQR,
0.7-1.2 × 109/L], respectively, P < .001), were more likely to
be admitted to the hospital (40% [39/97] vs 17% [38/231],
P < .001), and were more likely to receive granulocyte
colony–stimulating factor rescue therapy (20% [19/97] vs
5.2% [12/231], P < .001; eTables 10-11 in the Supplement).
The success of another challengewith thiopurine accord-
ing to genotype also was explored. Among the 51% (167/328)
of affected patients rechallenged, 57% (95/167) were able to
tolerate a lower dose (median successful rechallengedose, 1.2
mg/kg [IQR, 0.9-1.5 mg/kg]). Neither weight-adjusted dose,
type of thiopurine, patient age, TPMT genotype, norNUDT15
genotypewere associatedwith subsequent tolerance after re-
challenge (eTable 12 in the Supplement).
Multivariable Logistic Regression Analysis
In amultivariable logistic regressionmodel analysis, the odds
ofTIMamongpatientswithanyof 3 codingvariants inNUDT15
(OR, 27.3 [95%CI, 9.3 to 116.7]; P = 1.1 × 10−7) and inTPMT (in
heterozygotes: OR, 2.2 [95% CI, 1.4 to 3.3], P = 3.5 × 10−4; in
homozygotes: OR, 53.4 [95%CI, 10.4 to 980.1],P = 1.5 × 10−4)
were independentof thiopurine-weight adjusteddose (OR,2.2
[95% CI, 1.8 to 2.8], P = 5.3 × 10−11; Table 3).
Estimated Potential Clinical Effectiveness
ForNUDT15, theestimatednumberofpatientsneeded togeno-
type to prevent 1 patient from developing TIM was 95 pa-
tients (95%CI,62-143patients).Forevery10000patientsgeno-
typed, 164 would test positive for a NUDT15 variant, and of
these patients, 105wouldhavedevelopedTIM if theyhadnot
received an alternative treatment (positive predictive value,
64%[95%CI,43%-100%];eMethods in theSupplement).Geno-
typing 10000 patients for NUDT15 would prevent 105 cases
of TIM, which is 95 patients genotyped for every case pre-
vented. The number needed to genotype assumed a cumula-
tive incidence forTIMof 7%(95%CI, 6%-8%)basedonameta-
analysisof8302patients,1 adrugavoidancestrategy inNUDT15
variant carriers, a population carriage frequencyof 1.6% (95%
CI, 1.5%-1.8%), and ORs derived from bootstrapping the af-
fected and unaffected population (sampling with replace-
ment to estimate the variability of the OR). If a dose reduc-
tion strategywasused inNUDT15variant carriers instead, thus
reducing riskofTIMto thatofpatientswith the referencegeno-
type (absolute risk, 6% [95%CI, 5%-7%]), thenumber needed
to genotype would be 105 patients (95% CI, 65-168 patients).
ForTPMT, the estimatednumberneeded to genotypewas
123 patients (95% CI, 75-235 patients). For every 10000 pa-
tients genotyped, 100 would test positive for a TPMT variant
and need to receive an alternative therapy to prevent TIM in
8 patients (95% CI, 4-13 patients). This assumed the follow-
ing for patients carrying 2 TPMT variant haplotypes: drug
avoidance, apopulation carrier frequency30of0.26%(95%CI,
0.19%-0.34%), and anORof 53.4 (95%CI, 10.4-980.1). For pa-
tients carrying 1 TPMT haplotype, this assumed the follow-
ing: a thiopurine dose reduction, a population carrier fre-
quency of 9.7% (95% CI, 8.4%-11.0%), and an OR of 2.2 (95%
CI, 1.4-3.3).
In thewider cohort of 398 affected patientswhowere ad-
judicated and when including patients of non-European an-
cestry (who had been excluded from the GWAS and EWAS
analyses), carriageofNUDT15variantswasmore frequent than
in patients of non-Finnish European ancestry (100% [4/4] for
SouthAsianpatients vs9%[31/328] fornon-FinnishEuropean
patients, P = 1.1 × 10−4; and 56% [23/41] for East Asian pa-
tients vs 9% [31/328] non-Finnish European patients,
P = 2.0 × 10−11; eTable 13 in the Supplement).
Estimates of the rate of carrying 1 or more NUDT15 risk
alleles in the general population using the gnomAD reference
database ranged from 0.7% in patients of African ancestry to
29.2% in patients of East Asian ancestry (eTable 14 in the
Supplement).
Table 3. AssociationWith TPMT andNUDT15Variants on Clinical Phenotype inMultivariate Logistic RegressionModel Analysis
of Genetic and Dose-Related Factors AssociatedWith Thiopurine-InducedMyelosuppression (n = 919)a
Variable Odds Ratio (95% CI) P Valueb
Weight-adjusted thiopurine dosec 2.2 (1.8 to 2.8) 5.3 × 10−11
NUDT15 genotype
Reference genotype/reference genotype 1 [Reference]
Variant genotype/*d 27.3 (9.3 to 116.7) 1.1 × 10−7
TPMT haplotype
Reference haplotype/reference haplotype 1 [Reference]
Reference haplotype/variant haplotype 2.2 (1.4 to 3.3) 3.5 × 10−4
Variant haplotype/variant haplotype 53.4 (10.4 to 980.1) 1.5 × 10−4
a There were 42 observations missing.
b From logistic regression with all 3 variables included. P < .05 deemed
statistically significant.
c For every 1 mg/kg increase in azathioprine equivalent dose. Represents the
maximum azathioprine equivalent dose prior to thiopurine-induced
myelosuppression adjusted for weight (milligrams per kilograms).
d Carriage of 1 or more of 3NUDT15 variants: rs746071566 [p.Gly17_Val18del],
rs746071566 [p.Gly17_Val18dup], and rs116855232 [p.Arg139Cys]. One patient
with TIM possessed 2 NUDT15 variants (rs746071566 [p.Gly17_Val18dup] and
rs116855232 [p.Arg139Cys]); however, it was not possible to ascertain if this
represented a compound heterozygote or 2 variants on the same strand
(*2 NUDT15 haplotype). For the purpose of the analysis, this case was
considered as a single NUDT15 variant carrier (NUDT15 var/*).
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Discussion
In this case-control study involving both GWAS and EWAS
analyses, an association between an NUDT15 variant
(p.Gly17_Val18del) and TIM has been identified and repli-
cated in independent cohorts of patients of non-Finnish
Europeanancestry. In total, 3NUDT15 codingvariants, includ-
ing p.Gly17_Val18del, were identified and collectively associ-
ated with TIM independent of TPMT genotype and thiopu-
rine dose. Patients with variants of either NUDT15 or TPMT,
or among those with variants of both genes, had a faster on-
set of TIM,more severeTIM, andhadagreater need for granu-
locyte colony–stimulating factor rescue therapy.
Toour knowledge, this is the first study todescribe the as-
sociation of an NUDT15 variant with TIM in patients of
European ancestry at genome-wide significance. This ex-
tends previous work by Moriyama et al10 that first described
this p.Gly17_Val18del variant in 2pediatric patientswith acute
lymphoblastic leukemia and TIM; one of whomwas of Euro-
pean, and the second, of African ancestry.
Thep.Arg139Cysvarianthaspreviouslybeenassociatedwith
TIM in aNorthAmerican IBD cohort study forwhich theminor
allele frequencyreportedwas2.7%inaffectedpatientsand0.3%
inunaffectedpatients (OR,9.50;P = 4.6 × 10−4).9 Incontrast, to
our knowledge, thep.Gly17_Val18dupvariant hadonly been re-
ported in cohorts of East Asian ancestry.8
NUDT15 is hypothesized tohydrolyse nucleoside triphos-
phate activemetabolites (6-thio-dGTP,6-thio-GTP, anddGTP)
thuspreventingtheir incorporation intoDNAwhere theywould
otherwise lead to futile mismatch repair and apoptosis.8,9,31
Functional experiments confirm thatNUDT15 variants result
in lower enzymatic activity, leading to higher levels of thio-
purine active metabolites and a greater risk of TIM.8-10,31 The
p.Gly17_Val18dupvariant reducesNUDT15 activity to approxi-
mately 15% of normal activity, whereas p.Gly17_Val18del and
p.Arg139Cysarenearlyvoidofenzymeactivity, suggesting that
patients with these variants may be particularly sensitive to
thiopurines.8,10
Given the widespread use of the thiopurines, these find-
ings may have ramifications beyond the management of IBD
in patients of European ancestry. Although NUDT15 variants
were first associatedwithTIM inEastAsianpatientswith IBD,9
thisphenomenonhasnowbeendemonstrated inoncologyand
other immune-mediated diseases32,33 as well as in other
populations.9-14 For population stratification reasons, pa-
tients of non-European ancestry were excluded from the ge-
netic analyses of this study. However, it is interesting to note
in the absence of TPMT variants, the frequency of variant
NUDT15 haplotypes is 29.2% in populations of East Asian an-
cestry compared with 20.7% in Latin American populations,
13.4% in South Asian populations, and 1.6% in non-Finnish
European populations.25
As expected, in thewider cohort of affected patientswho
were adjudicated, patients of non-European descent demon-
strated a higher carriage frequency ofNUDT15 variants and a
lower carriage frequencyofTPMTvariants. If replicated in ad-
ditional studies, these findings suggest that NUDT15 testing
may be considered prior to thiopurine therapy irrespective of
the ethnic background of the patient.
The positive predictive value ofNUDT15 genotyping esti-
mated in this study together with the recent development of
alternative but more expensive therapies suggests potential
clinical utility of pretreatment testing and drug avoidance in
genetically at-risk patients. Recommendations regardingpre-
treatmentNUDT15 genotyping based on data fromEast Asian
populations are under reviewby theClinical Pharmacogenet-
ics Implementation Consortium.27 Our data suggest that pre-
treatment sequencing of the NUDT15 gene, including the
p.Gly17_Val18del deletion,may also be considered in patients
of European ancestry. However, this will not obviate the re-
quirement for regularmonitoringwith blood tests for the du-
rationof treatment amongpatients deemedat low riskofTIM.
The estimatednumber of patients needed to genotype for
NUDT15 is 95, similar to the number needed to genotype re-
ported herein and by others34 for TPMT (123 and 100, respec-
tively). However, further validation studies including a cost-
effectiveness analysis should be conducted prior to
implementation of pretreatment NUDT15 genotyping.
Limitations
This study has several limitations. First, inclusion was re-
stricted to patients with IBD of non-Finnish European ances-
try. Further research is required to evaluate the association of
thesevariantswithTIM inother ancestries anddiseasegroups.
Second, the replication cohort was not exclusively recruited
from independent sites. Thecentral site recruitedaffectedand
unaffected patients to the discovery cohort and then addi-
tional patients to the replication cohorts.
Third, inkeepingwithall case-control studies, thedata are
likely to be susceptible to recall bias and therewas greater re-
cruitmentofmore severely affectedpatients.Weestimate that
our affected patients represent 5% of the total eligible pa-
tients with IBD and an episode of TIM. This is based on a UK
IBD prevalence of 388 patients per 100000 population,35 a
thiopurine exposure rate of 31%,36 and a rate of TIM of 7%.1
This recall bias might explain the IBD phenotype differences
observed between cases and controls and an overestimate of
the risk associated with NUDT15 variants and TIM.
Fourth, 4.9% (16/328) of affected and0.2% (1/633) of unaf-
fected patients had 2 of the knownTIM-associatedTPMT vari-
ant haplotypes despite the recommended practice of pretreat-
ment measurement of TPMT enzyme activity and thiopurine
avoidance inpatientsdeficientofTPMTenzymeactivity.These
patients arguably should not have received treatment with a
thiopurine, regardless of the presence ofNUDT15 variants.
Fifth, theproposedmitigationstrategyof thiopurineavoid-
ance rather thandose reduction inpatientswithNUDT15 cod-
ing variants may be overly cautious. Previous studies in pa-
tients of East Asian ancestry have shown that even patients
with 2 low-functioning NUDT15 alleles may successfully tol-
erate a dose reduction of thiopurine by 90%.8,31,33 Likewise,
in NUDT15 knockout mice models, accumulation of thiopu-
rinemetabolites was noted to be in anmercaptopurine dose–
related fashion, suggesting thatdose reductionmightbeanef-
fective strategy.31However, asdiscussedabove,not all variants
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affectNUDT15 enzymatic function to the sameextent and the
magnitudeof thedeleterious effect of individual variantsmay
differ across ethnic groups.37 Furthermore, it is unknown
whether suchamarkeddose reductionwouldcompromise the
therapeutic effect of thiopurines in patients with IBD. In our
study of patients of non-Finnish European ancestry, almost
50%of patientswith a single variant did not tolerate a rechal-
lenge with thiopurine at a lower dose. These arguments may
justify theuse of alternative,more expensive therapies in this
small group of patients at high risk of TIM. However, further
data are needed to explore whether thiopurine dose reduc-
tionwith enhancedmonitoring or drug avoidance is the safer,
less expensive, and more clinically effective strategy.
Conclusions
Among patients of European ancestry with IBD, variants in
NUDT15wereassociatedwith increasedriskofTIM.These find-
ings suggest thatNUDT15 genotypingmay be considered prior
toinitiationofthiopurinetherapy;however,furtherstudyinclud-
ing additional validation in independent cohorts is required.
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